Should I Buy TOI? TOI 2026 Analysis

Should You Buy Oncology Institute Inc (TOI) Today? Analysis, Price Targets, and 2026 Outlook.

Conclusion

Hold

Latest Price

3.000

1 Day change

-1.96%

52 Week Range

4.880

Analysis Updated At

2026/01/26

Oncology Institute Inc (TOI) is not a strong buy at the moment for a beginner investor with a long-term focus. While the company shows promising growth potential in revenue and demand for its services, current technical indicators, hedge fund selling trends, and weak financial performance with negative net income and declining EPS suggest caution. The lack of strong positive trading signals and recent news further supports a hold recommendation.

Technical Analysis

The MACD is negative and expanding, indicating bearish momentum. RSI is neutral at 37.258, showing no clear signal. Moving averages are converging, and the stock is trading near its support level of 3.256, with resistance at 4.23. Overall, the technical indicators do not suggest a strong buy opportunity.

Options Data

Bullish

Open Interest Put-Call Ratio

Bullish

Option Volume Put-Call Ratio

Technical Summary

Sell

Buy

Positive Catalysts

Analysts from Needham initiated a Buy rating with a $5 price target, citing the company's potential to address rising oncology costs and a durable 20%+ growth outlook. The shift toward value-based care could improve EBITDA margins over the medium term.

Neutral/Negative Catalysts

Hedge funds are selling heavily, with a 47487.34% increase in selling activity over the last quarter. The company's financials show negative net income, declining EPS, and reduced gross margins. Technical indicators suggest bearish momentum, and there is no recent news or congress trading activity to support a positive sentiment.

Financial Performance

In Q3 2025, revenue increased by 36.70% YoY to $136.56M, but net income remained negative at -$13.77M, improving only 4.14% YoY. EPS dropped by -22.22% YoY to -0.14, and gross margin declined slightly to 12.59%. While revenue growth is strong, profitability metrics remain weak.

Growth

Profitability

Efficiency

Analyst Ratings and Price Target Trends

Needham analysts initiated coverage with a Buy rating and a $5 price target, citing the company's positioning in value-based care and potential for durable 20%+ growth. However, the stock is currently undervalued and expected to achieve positive EBITDA by Q4 FY26.

3 Analyst Rating

Wall Street analysts forecast TOI stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for TOI is 6.67 USD with a low forecast of 5 USD and a high forecast of 8 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

3 Buy

0 Hold

0 Sell

Strong Buy

Current: 3.060

Low

Averages

6.67

High

Current: 3.060

Low

Averages

6.67

High

Needham

Buy

initiated

AI Analysis

2025-11-25

Reason

Needham

Price Target

AI Analysis

2025-11-25

initiated

Buy

Reason

Needham initiated coverage of Oncology Institute with a Buy rating and $5 price target. As value-based care adoption accelerates, Oncology Institute appears well positioned to help curb rising oncology costs, with early relationships typically starting in fee-for-service and expanding into downside risk, the analyst tells investors in a research note. Demand supports a durable 20%+ growth outlook, a shift toward VBC could lift EBITDA margins into the mid-single digits, and shares look undervalued ahead of expected positive EBITDA in Q4 and FY26, the firm says.

Needham

Matthew Shea

initiated

2025-11-25

Reason

Needham

Matthew Shea

Price Target

2025-11-25

initiated

Reason

Needham analyst Matthew Shea initiated coverage of Oncology Institute with a Buy rating and $5 price target. The need for solutions that can mitigate oncology cost trends "could not be more apparent," says the analyst, who views Oncology Institute as "a critical player in addressing this gap." The firm sees demand seeding durable 20%-plus topline growth and sees an opportunity for EBITDA margins to scale towards mid-single digits over the medium term as mix shifts towards value-based care, the analyst tells investors.

Unlock Full Analyst Thesis， Get the complete breakdown of rating reason for TOI

Unlock Now

TOI Should I Buy

TOI Should I Buy

Should You Buy Oncology Institute Inc (TOI) Today? Analysis, Price Targets, and 2026 Outlook.

Technical Analysis

Options Data

Technical Summary

Positive Catalysts

Neutral/Negative Catalysts

Financial Performance

Growth

Profitability

Efficiency

Analyst Ratings and Price Target Trends

People Also Watch